- $522.12m
- $50.73m
- $135.16m
- 51
- 30
- 13
- 22
Annual income statement for Prothena, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.853 | 201 | 53.9 | 91.4 | 135 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 114 | 129 | 185 | 282 | 290 |
| Operating Profit | -113 | 72 | -132 | -191 | -155 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -111 | 71.9 | -126 | -160 | -129 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -111 | 67 | -117 | -147 | -122 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -111 | 67 | -117 | -147 | -122 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -111 | 67 | -117 | -147 | -122 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.78 | 1.38 | -2.47 | -2.76 | -2.27 |